pembrolizumab,lenvatinib,BLI4900,camrelizumab,Rivoceranib,Regorafenib,ipilimumab,nivolumab,cabozantinib,Atezolizumab,Bevacizumab,Sorafenib,Durvalumab,Tremelimumab
Merck,eisai,jiangsu hengrui pharmaceuticals,elevar therapeutics,bayer,exelixis,bms,roche,astrazeneca,pfizer
['hcc', 'leap-002', 'card', 'rivoceranib', 'lenva', 'pembro', 'camrelizumab']
following #leap-002 (lenva/pembro) and study-302 (rivoceranib/camrelizumab) presentations at #esmo, an updated scorecard for doublet therapy in 1l #hcc 
Medical oncologist @ Johns Hopkins, focused on translational research for hepatobiliary cancers (HCC, cholangiocarcinoma)